Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Cash & Equivalents: 2013-2025

Historic Cash & Equivalents for Amphastar Pharmaceuticals (AMPH) over the last 13 years, with Sep 2025 value amounting to $216.3 million.

  • Amphastar Pharmaceuticals' Cash & Equivalents rose 12.57% to $216.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $216.3 million, marking a year-over-year increase of 12.57%. This contributed to the annual value of $151.6 million for FY2024, which is 5.07% up from last year.
  • Amphastar Pharmaceuticals' Cash & Equivalents amounted to $216.3 million in Q3 2025, which was up 15.23% from $187.7 million recorded in Q2 2025.
  • Amphastar Pharmaceuticals' 5-year Cash & Equivalents high stood at $266.8 million for Q3 2023, and its period low was $101.6 million during Q1 2021.
  • For the 3-year period, Amphastar Pharmaceuticals' Cash & Equivalents averaged around $187.0 million, with its median value being $187.7 million (2025).
  • In the last 5 years, Amphastar Pharmaceuticals' Cash & Equivalents surged by 79.16% in 2021 and then decreased by 27.99% in 2024.
  • Quarterly analysis of 5 years shows Amphastar Pharmaceuticals' Cash & Equivalents stood at $126.4 million in 2021, then climbed by 23.54% to $156.1 million in 2022, then declined by 7.56% to $144.3 million in 2023, then rose by 5.07% to $151.6 million in 2024, then increased by 12.57% to $216.3 million in 2025.
  • Its last three reported values are $216.3 million in Q3 2025, $187.7 million for Q2 2025, and $182.8 million during Q1 2025.